X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SANOFI INDIA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SANOFI INDIA IPCA LABS/
SANOFI INDIA
 
P/E (TTM) x 29.3 32.4 90.5% View Chart
P/BV x 4.3 5.7 75.8% View Chart
Dividend Yield % 0.1 1.5 7.1%  

Financials

 IPCA LABS   SANOFI INDIA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
SANOFI INDIA
Dec-18
IPCA LABS/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs6956,840 10.2%   
Low Rs4004,630 8.6%   
Sales per share (Unadj.) Rs260.21,203.1 21.6%  
Earnings per share (Unadj.) Rs19.0165.3 11.5%  
Cash flow per share (Unadj.) Rs33.1209.9 15.8%  
Dividends per share (Unadj.) Rs1.0084.00 1.2%  
Dividend yield (eoy) %0.21.5 12.5%  
Book value per share (Unadj.) Rs213.0963.6 22.1%  
Shares outstanding (eoy) m126.2023.03 548.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.8 44.2%   
Avg P/E ratio x28.934.7 83.2%  
P/CF ratio (eoy) x16.627.3 60.6%  
Price / Book Value ratio x2.66.0 43.2%  
Dividend payout %5.350.8 10.4%   
Avg Mkt Cap Rs m69,120132,078 52.3%   
No. of employees `00013.33.3 401.5%   
Total wages/salary Rs m7,3594,068 180.9%   
Avg. sales/employee Rs Th2,477.48,393.8 29.5%   
Avg. wages/employee Rs Th555.21,232.4 45.1%   
Avg. net profit/employee Rs Th180.61,153.0 15.7%   
INCOME DATA
Net Sales Rs m32,83627,708 118.5%  
Other income Rs m418897 46.6%   
Total revenues Rs m33,25428,605 116.3%   
Gross profit Rs m4,5056,235 72.3%  
Depreciation Rs m1,7771,027 173.1%   
Interest Rs m2407 3,431.4%   
Profit before tax Rs m2,9056,098 47.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5112,292 22.3%   
Profit after tax Rs m2,3943,806 62.9%  
Gross profit margin %13.722.5 61.0%  
Effective tax rate %17.637.6 46.8%   
Net profit margin %7.313.7 53.1%  
BALANCE SHEET DATA
Current assets Rs m19,45515,922 122.2%   
Current liabilities Rs m10,0766,235 161.6%   
Net working cap to sales %28.635.0 81.7%  
Current ratio x1.92.6 75.6%  
Inventory Days Days9864 153.8%  
Debtors Days Days6721 320.8%  
Net fixed assets Rs m20,2607,539 268.7%   
Share capital Rs m252230 109.7%   
"Free" reserves Rs m26,63321,962 121.3%   
Net worth Rs m26,88622,192 121.2%   
Long term debt Rs m2,3400-   
Total assets Rs m41,17329,839 138.0%  
Interest coverage x13.1872.1 1.5%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.9 85.9%   
Return on assets %6.412.8 50.1%  
Return on equity %8.917.2 51.9%  
Return on capital %10.827.5 39.1%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,6427,587 206.2%   
Fx outflow Rs m4,8847,145 68.3%   
Net fx Rs m10,759442 2,434.0%   
CASH FLOW
From Operations Rs m3,4113,739 91.2%  
From Investments Rs m-1,354-731 185.2%  
From Financial Activity Rs m-1,304-1,972 66.1%  
Net Cashflow Rs m7531,036 72.7%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 11.4 14.4 79.2%  
FIIs % 25.3 14.6 173.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.5 165.7%  
Shareholders   36,892 15,184 243.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SUN PHARMA  MERCK  ABBOTT INDIA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Motors Down Over 5%(12:30 pm)

Share markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the realty sector and energy sector.

Related Views on News

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 21, 2019 12:49 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS